A multicenter phase I/II study of enzalutamide in Japanese patients with castration-resistant prostate cancer

被引：7
|
作者：
Akaza, Hideyuki [1 ]
Uemura, Hirotsugu [2 ]
Tsukamoto, Taiji [3 ]
Ozono, Seiichiro [4 ]
Ogawa, Osamu [5 ]
Sakai, Hideki [6 ]
Oya, Mototsugu [7 ]
Namiki, Mikio [8 ]
Fukasawa, Satoshi [9 ]
Yamaguchi, Akito [10 ]
Uemura, Hiroji [11 ]
Ohashi, Yasuo [12 ]
Maeda, Hideki [13 ]
Saito, Atsushi [13 ]
Takeda, Kentaro [13 ]
Naito, Seiji [10 ]
机构：
[1] Univ Tokyo, Strateg Invest Comprehens Canc Network, Meguro Ku, 4-6-1 Komaba, Tokyo 1538904, Japan
[2] Kinki Univ, Dept Urol, Fac Med, 377-2 Ono Higashi, Osakasayama 5898511, Japan
[3] Sapporo Med Univ, Dept Urol, Sch Med, S1 W17 Chuo Ku, Sapporo, Hokkaido 0608556, Japan
[4] Hamamatsu Univ Sch Med, Dept Urol, Higashi Ku, 1-20-1 Handayama, Hamamatsu, Shizuoka 4313192, Japan
[5] Kyoto Univ, Dept Urol, Grad Sch Med, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan
[6] Nagasaki Univ, Dept Urol, Grad Sch Biomed Sci, 1-7-1 Sakamoto, Nagasaki 8528501, Japan
[7] Keio Univ, Dept Urol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan
[8] Kanazawa Univ, Dept Integrat Canc Therapy & Urol, Grad Sch Med Sci, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan
[9] Chiba Canc Ctr, Dept Urol, Chuo Ku, 666-2 Nitona Cho, Chiba 2608717, Japan
[10] Harasanshin Hosp, Div Urol, Hakata Ku, 1-8 Taihakumachi, Fukuoka 8120033, Japan
[11] Yokohama City Univ, Dept Urol & Renal Transplantat, Med Ctr, Minami Ku, 4-57 Urafune, Yokohama, Kanagawa 2320024, Japan
[12] Chuo Univ, Dept Integrated Sci & Engn Sustainable Soc, Bunkyo Ku, 1-13-27 Kasuga, Tokyo 1128551, Japan
[13] Astellas Pharma Inc, Chuo Ku, 2-5-1 Nihonbashi Honcho, Tokyo 1038411, Japan
来源：
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 21卷 / 04期
关键词：
Androgen receptor inhibitor; Enzalutamide; Metastatic castration-resistant prostate cancer; ABIRATERONE ACETATE; ANTITUMOR-ACTIVITY; INCREASED SURVIVAL; CLINICAL ACTIVITY; DOCETAXEL; THERAPY; TRIAL; PREDNISOLONE; MITOXANTRONE; ANTIANDROGEN;
D O I：
10.1007/s10147-016-0952-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Trial registration: ClinicalTrials.gov NCT01284920.
引用
收藏
页码：773 / 782
页数：10
相关论文
共 50 条
  • [31] Sequencing Treatment for Castration-Resistant Prostate Cancer
    Handy, Catherine E.
    Antonarakis, Emmanuel S.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (12)
  • [32] Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer
    Nozawa, Masahiro
    Mukai, Hirofumi
    Takahashi, Shunji
    Uemura, Hiroji
    Kosaka, Takeo
    Onozawa, Yusuke
    Miyazaki, Jun
    Suzuki, Kazuhiro
    Okihara, Koji
    Arai, Yoichi
    Kamba, Tomomi
    Kato, Masashi
    Nakai, Yasutomo
    Furuse, Hiroshi
    Kume, Haruki
    Ide, Hisamitsu
    Kitamura, Hiroshi
    Yokomizo, Akira
    Kimura, Takahiro
    Tomita, Yoshihiko
    Ohno, Keiji
    Kakehi, Yoshiyuki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2015, 20 (05) : 1026 - 1034
  • [33] Enzalutamide in Castration-resistant Prostate Cancer Patients Progressing After Docetaxel and Abiraterone
    Schrader, Andres Jan
    Boegemann, Martin
    Ohlmann, Carsten-H.
    Schnoeller, Thomas J.
    Krabbe, Laura-Maria
    Hajili, Turkan
    Jentzmik, Florian
    Stoeckle, Michael
    Schrader, Mark
    Herrmann, Edwin
    Cronauer, Marcus V.
    EUROPEAN UROLOGY, 2014, 65 (01) : 30 - 36
  • [34] Sequencing new agents after docetaxel in patients with metastatic castration-resistant prostate cancer
    Maines, Francesca
    Caffo, Orazio
    Veccia, Antonello
    Trentin, Chiara
    Tortora, Giampaolo
    Galligioni, Enzo
    Bria, Emilio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 96 (03) : 498 - 506
  • [35] Predicting Response and Recognizing Resistance: Improving Outcomes in Patients With Castration-resistant Prostate Cancer
    Shore, Neal
    Heidenreich, Axel
    Saad, Fred
    UROLOGY, 2017, 109 : 6 - 16
  • [36] Efficacy of Enzalutamide Following Abiraterone Acetate in Chemotherapy- naive Metastatic Castration-resistant Prostate Cancer Patients
    Azad, Arun A.
    Eigl, Bernhard J.
    Murray, R. Nevin
    Kollmannsberger, Christian
    Chi, Kim N.
    EUROPEAN UROLOGY, 2015, 67 (01) : 23 - 29
  • [37] A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer
    Ueda, Yujiro
    Matsubara, Nobuaki
    Takizawa, Itsuhiro
    Nishiyama, Tsutomu
    Tabata, Ken-ichi
    Satoh, Takefumi
    Kamiya, Naoto
    Suzuki, Hiroyoshi
    Kawahara, Takashi
    Uemura, Hiroji
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2015, 45 (08) : 774 - 779
  • [38] Management of Castration-Resistant, Taxane-Resistant Prostate Cancer
    Beer, Tomasz M.
    ONCOLOGY-NEW YORK, 2017, 31 (08): : 633 - 636
  • [39] Metastasis-directed stereotactic radiotherapy for oligoprogressive castration-resistant prostate cancer: a multicenter study
    Triggiani, Luca
    Mazzola, Rosario
    Magrini, Stefano Maria
    Ingrosso, Gianluca
    Borghetti, Paolo
    Trippa, Fabio
    Lancia, Andrea
    Detti, Beatrice
    Francolini, Giulio
    Matrone, Fabio
    Bortolus, Roberto
    Fanetti, Giuseppe
    Maranzano, Ernesto
    Pasqualetti, Francesco
    Paiar, Fabiola
    Bonu, Marco Lorenzo
    Magli, Alessandro
    Bruni, Alessio
    Mazzeo, Ercole
    Franzese, Ciro
    Scorsetti, Marta
    Alongi, Filippo
    Jereczek-Fossa, Barbara Alicja
    Ost, Piet
    Buglione, Michela
    WORLD JOURNAL OF UROLOGY, 2019, 37 (12) : 2631 - 2637
  • [40] A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone
    Graff, Julie N.
    Beer, Tomasz M.
    Alumkal, Joshi J.
    Slottke, Rachel E.
    Redmond, William L.
    Thomas, George, V
    Thompson, Reid F.
    Wood, Mary A.
    Koguchi, Yoshinobu
    Chen, Yiyi
    Latour, Emile
    Bergan, Raymond C.
    Drake, Charles G.
    Moran, Amy E.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
12345